Zila divertiture approved
This article was originally published in The Tan Sheet
Executive Summary
Zila receives shareholder approval to divest wholly-owned subsidiary Zila Nutraceuticals to NBTY, the Phoenix-based firm announces Sept. 28. The company expects the divestiture to be completed Oct. 2 for $37.5 mil. in a total cash transaction with up to an additional $3 mil. to be paid through an "earn-out formula dependent upon the future performance of the business." NBTY in August announced the proposed acquisition of the nutraceutical division, which includes the Ester-C and Ester-E branded ingredients (1"The Tan Sheet," Aug. 21, 2006, p. 5)...
You may also be interested in...
NBTY Expands Into Mass Market With Zila Acquisition
NBTY is looking to use Ester-C brand recognition and loyalty to gain traction in the mass retail market
EWG’s 2023 Sunscreen Guide: Oxybenzone Use Down, ‘EWG Verified’ Products Up
The Environmental Working Group’s annual sunscreen report finds that one in four products evaluated meet its standards for protection and ingredient avoidance, fairly consistent with the past three years but still worse than 2019. This year, “gold standard” sunscreen products bear the nonprofit’s “Verified” mark.
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.